Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT2 | O60551 | 2/20 | 0.47 |
| ▸ | NMT1 | P30419 | 2/20 | 0.47 |
| ▸ | GLP1R | P43220 | 8/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19156036 | 0.95 | NMT2 (0.52) | NMT2NMT1GLP1RNOD1TLR2 | |
| SCHEMBL22227375 | 0.95 | NMT2 (0.52) | NMT2NMT1GLP1RNOD1TLR2 | |
| SCHEMBL19062765 | 0.95 | NMT1 (0.49) | NMT2NMT1GLP1RNOD1TLR2 | |
| SCHEMBL21154993 | 0.94 | NMT2 (0.50) | NMT2NMT1GLP1RNOD1TLR2 | |
| SCHEMBL22692638 | 0.94 | NMT2 (0.50) | NMT2NMT1GLP1RNOD1TLR2 | |
| SCHEMBL22692642 | 0.89 | NOD1 (0.46) | GLP1RNOD1TLR2MEN1FAAH | |
| SCHEMBL18513227 | 0.89 | NMT1 (0.54) | NMT2NMT1GLP1RNOD1TLR2 | |
| SCHEMBL24119975 | 0.88 | NMT2 (0.46) | NMT2NMT1GLP1RNOD1TLR2 | |
| SCHEMBL22912627 | 0.88 | NOD1 (0.44) | GLP1RNOD1TLR2MEN1FAAH | |
| SCHEMBL20053468 | 0.88 | TLR2 (0.49) | NMT2NMT1GLP1RNOD1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844379-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844379-B2 | Conjugated antisense compounds and their use | CSGALNACT1, GALNT1, GALNT6 | NMT2 27/4885NMT1 30/4885GLP1R 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.